STACEY BERG

Concepts (344)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
31
2021
1661
2.550
Why?
Neoplasms
35
2024
2758
2.180
Why?
Leukemia
10
2019
375
1.040
Why?
Antineoplastic Combined Chemotherapy Protocols
10
2024
1227
0.920
Why?
Pyrimidines
6
2024
373
0.850
Why?
Thalidomide
3
2011
36
0.800
Why?
Neuroblastoma
7
2021
509
0.780
Why?
Arabinonucleosides
3
2006
32
0.770
Why?
Protein Kinase Inhibitors
6
2021
522
0.750
Why?
Azepines
3
2019
61
0.690
Why?
Medical Oncology
4
2010
214
0.680
Why?
Vincristine
2
2021
195
0.650
Why?
Meningeal Neoplasms
7
2011
183
0.650
Why?
Neoplasm Recurrence, Local
13
2024
1117
0.640
Why?
Maximum Tolerated Dose
14
2024
157
0.560
Why?
Child
50
2024
24237
0.560
Why?
Salvage Therapy
5
2019
193
0.550
Why?
Antineoplastic Agents, Alkylating
4
2010
99
0.550
Why?
Child, Preschool
38
2024
13887
0.530
Why?
Drug Therapy
1
2016
87
0.530
Why?
Antineoplastic Agents, Phytogenic
2
2015
102
0.530
Why?
Piperazines
4
2024
230
0.520
Why?
Pharmaceutical Preparations
1
2016
80
0.520
Why?
Drugs, Essential
3
2023
7
0.510
Why?
Macaca mulatta
12
2011
494
0.490
Why?
Benzimidazoles
2
2022
129
0.490
Why?
Dacarbazine
3
2011
86
0.490
Why?
Central Nervous System Neoplasms
4
2024
194
0.480
Why?
Oxygenases
1
2014
4
0.480
Why?
Daunorubicin
1
2014
27
0.470
Why?
Histone Deacetylase Inhibitors
3
2012
74
0.470
Why?
Glutathione S-Transferase pi
1
2014
25
0.470
Why?
O(6)-Methylguanine-DNA Methyltransferase
3
2009
20
0.470
Why?
Adolescent
39
2024
19103
0.460
Why?
Peripheral Nervous System Diseases
1
2015
128
0.460
Why?
Microtubule-Associated Proteins
1
2015
245
0.450
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
2020
804
0.450
Why?
Decision Support Techniques
1
2016
280
0.440
Why?
Drug Resistance, Neoplasm
9
2024
714
0.440
Why?
Area Under Curve
12
2021
313
0.430
Why?
Antibiotics, Antineoplastic
3
2014
126
0.430
Why?
Clinical Trials, Phase I as Topic
2
2010
57
0.430
Why?
Young Adult
21
2024
8863
0.400
Why?
Hydroxamic Acids
1
2012
56
0.400
Why?
Guanine
3
2011
60
0.400
Why?
Camptothecin
3
2008
76
0.400
Why?
Enzyme Inhibitors
5
2009
572
0.390
Why?
Sarcoma, Ewing
3
2022
113
0.390
Why?
Poly(ADP-ribose) Polymerase Inhibitors
2
2024
28
0.390
Why?
Doxorubicin
2
2014
299
0.380
Why?
Informed Consent
3
2009
341
0.380
Why?
Patient Participation
3
2010
220
0.360
Why?
Humans
68
2024
123171
0.360
Why?
Male
49
2024
60084
0.360
Why?
Body Composition
2
2014
513
0.350
Why?
Obesity
2
2014
2227
0.350
Why?
Metabolic Clearance Rate
5
2014
142
0.350
Why?
Dose-Response Relationship, Drug
10
2018
1683
0.350
Why?
Myelodysplastic Syndromes
1
2010
137
0.330
Why?
Antimetabolites, Antineoplastic
4
2020
178
0.330
Why?
Chromatography, High Pressure Liquid
8
2011
338
0.320
Why?
Carboxylic Acids
1
2008
24
0.320
Why?
Rhabdomyosarcoma
2
2022
200
0.320
Why?
Infant
21
2024
12348
0.320
Why?
Boronic Acids
2
2005
48
0.310
Why?
Medulloblastoma
2
2012
338
0.310
Why?
Cyclophosphamide
2
2008
419
0.310
Why?
Physician-Patient Relations
2
2009
428
0.310
Why?
Pyrazines
2
2005
73
0.310
Why?
Oligopeptides
1
2008
118
0.310
Why?
Cyclin-Dependent Kinase 6
2
2024
38
0.290
Why?
Cyclin-Dependent Kinase 4
2
2024
54
0.290
Why?
Clinical Trials as Topic
2
2009
1088
0.290
Why?
Phthalazines
2
2024
14
0.280
Why?
Female
42
2024
65500
0.270
Why?
Polymorphism, Single Nucleotide
1
2015
2586
0.270
Why?
Infusions, Intravenous
8
2005
537
0.270
Why?
Indoles
2
2004
180
0.260
Why?
Topotecan
3
2012
49
0.250
Why?
Leukemia, T-Cell
1
2005
12
0.250
Why?
Ethics, Medical
2
2007
395
0.250
Why?
Protease Inhibitors
1
2005
94
0.250
Why?
DNA Repair
3
2024
579
0.240
Why?
Cell Line, Tumor
6
2018
3273
0.240
Why?
Cyclopentanes
1
2024
20
0.230
Why?
Cyclin D1
1
2004
111
0.230
Why?
Depsipeptides
1
2004
10
0.230
Why?
Cyclins
1
2004
101
0.230
Why?
Carbazoles
1
2004
32
0.230
Why?
Cisplatin
2
2004
242
0.230
Why?
Peptides, Cyclic
1
2004
52
0.220
Why?
Rhabdoid Tumor
1
2023
49
0.220
Why?
Parents
3
2009
1030
0.220
Why?
Glioma
2
2022
496
0.210
Why?
Methotrexate
2
2020
341
0.210
Why?
Pyridines
1
2024
224
0.210
Why?
Proto-Oncogene Proteins B-raf
1
2024
164
0.210
Why?
Adult
19
2024
29062
0.200
Why?
Models, Theoretical
1
2004
356
0.200
Why?
TOR Serine-Threonine Kinases
1
2024
426
0.190
Why?
Treatment Outcome
14
2020
12129
0.190
Why?
Dactinomycin
1
2021
67
0.190
Why?
Injections, Spinal
6
2011
117
0.180
Why?
Maytansine
1
2020
3
0.180
Why?
Neurofibrosarcoma
1
2020
5
0.180
Why?
Pulmonary Blastoma
1
2020
11
0.180
Why?
Sarcoma, Synovial
1
2020
21
0.180
Why?
Sodium Bicarbonate
1
2020
52
0.170
Why?
Protein-Tyrosine Kinases
2
2019
211
0.170
Why?
Drug Synergism
3
2009
239
0.170
Why?
Drug Interactions
3
2012
254
0.170
Why?
National Cancer Institute (U.S.)
3
2024
28
0.160
Why?
Wilms Tumor
1
2020
111
0.160
Why?
Cerebrospinal Fluid
3
2004
93
0.160
Why?
Research Subjects
1
2019
55
0.160
Why?
Antineoplastic Agents, Immunological
1
2020
99
0.160
Why?
Drug Administration Schedule
6
2018
730
0.150
Why?
Topoisomerase I Inhibitors
2
2011
16
0.150
Why?
Antibodies, Monoclonal
2
2024
1008
0.150
Why?
Lymphoma, Non-Hodgkin
1
2020
162
0.150
Why?
Bone Neoplasms
2
2019
427
0.150
Why?
Research Personnel
1
2019
117
0.150
Why?
Furans
1
2018
27
0.150
Why?
Inhibitory Concentration 50
3
2014
75
0.150
Why?
Ketones
1
2018
24
0.150
Why?
Health Services Accessibility
2
2023
594
0.150
Why?
Cell Cycle Proteins
2
2019
644
0.150
Why?
Aurora Kinase A
1
2018
40
0.150
Why?
Recurrence
3
2019
1422
0.140
Why?
Animals
16
2019
33749
0.140
Why?
Hodgkin Disease
1
2020
293
0.140
Why?
Cell Survival
2
2012
806
0.140
Why?
Health Policy
1
2019
213
0.140
Why?
Mass Spectrometry
3
2006
326
0.130
Why?
Brain Neoplasms
2
2004
1235
0.130
Why?
Health Care Rationing
1
2016
58
0.130
Why?
Palliative Care
1
2019
429
0.120
Why?
Pediatrics
3
2010
1139
0.120
Why?
Deoxycytidine
2
2007
75
0.120
Why?
Molecular Targeted Therapy
2
2022
353
0.120
Why?
Drug Screening Assays, Antitumor
1
2014
94
0.120
Why?
Prodrugs
2
2006
59
0.120
Why?
Glioblastoma
1
2018
334
0.110
Why?
Absorptiometry, Photon
1
2014
178
0.110
Why?
Separase
1
2014
29
0.110
Why?
Clinical Decision-Making
1
2016
265
0.110
Why?
Biomedical Research
1
2019
518
0.110
Why?
Pregnancy Complications, Neoplastic
1
2014
62
0.110
Why?
Mutation
2
2024
5773
0.110
Why?
Pharmacogenetics
1
2014
183
0.110
Why?
Tumor Cells, Cultured
2
2005
1061
0.110
Why?
Neoplasm Staging
2
2008
1213
0.110
Why?
Practice Guidelines as Topic
2
2017
1262
0.110
Why?
Injections, Intravenous
3
2008
252
0.110
Why?
Meningitis, Aseptic
1
2012
14
0.100
Why?
Haplotypes
1
2014
519
0.100
Why?
Aurora Kinase B
1
2012
8
0.100
Why?
Aurora Kinases
1
2012
31
0.100
Why?
Pyrroles
2
2024
177
0.100
Why?
Mitogen-Activated Protein Kinases
2
2024
206
0.100
Why?
Survival Rate
4
2019
1996
0.100
Why?
Models, Statistical
1
2014
475
0.100
Why?
Genomics
1
2019
1478
0.100
Why?
Brain Stem Neoplasms
1
2011
39
0.090
Why?
Lung Neoplasms
1
2021
1582
0.090
Why?
Polymorphism, Genetic
1
2014
809
0.090
Why?
Half-Life
4
2021
156
0.090
Why?
Prognosis
4
2019
4507
0.090
Why?
Organoplatinum Compounds
1
2010
29
0.090
Why?
Blood-Brain Barrier
2
2018
141
0.090
Why?
Disease Models, Animal
4
2019
4271
0.090
Why?
United States
6
2024
10631
0.090
Why?
Altruism
1
2010
25
0.090
Why?
Immunity, Cellular
1
2010
203
0.080
Why?
DNA Mismatch Repair
1
2009
48
0.080
Why?
Survival Analysis
3
2020
1472
0.080
Why?
Apoptosis
3
2018
1781
0.080
Why?
Drug Discovery
1
2010
170
0.080
Why?
Tissue Distribution
2
2019
382
0.080
Why?
Acyclovir
1
2008
45
0.080
Why?
Bortezomib
2
2005
73
0.080
Why?
Valine
1
2008
106
0.080
Why?
Body Mass Index
1
2014
1541
0.080
Why?
Carmustine
1
2008
26
0.080
Why?
Confidentiality
1
2008
101
0.070
Why?
Follow-Up Studies
4
2019
5047
0.070
Why?
Human Experimentation
1
2007
37
0.070
Why?
Ethics, Research
1
2007
50
0.070
Why?
Carboplatin
2
2004
75
0.070
Why?
Genome-Wide Association Study
1
2014
1641
0.070
Why?
Erythropoietin
1
2007
104
0.070
Why?
Administration, Intravenous
2
2020
143
0.070
Why?
DNA Damage
2
2024
505
0.070
Why?
Benzamides
2
2023
106
0.070
Why?
Valproic Acid
1
2007
165
0.070
Why?
Immunocompromised Host
1
2008
300
0.070
Why?
Proto-Oncogene Proteins c-mdm2
1
2006
79
0.070
Why?
Adenine Nucleotides
1
2005
41
0.060
Why?
Xenograft Model Antitumor Assays
2
2019
877
0.060
Why?
Administration, Oral
3
2018
670
0.060
Why?
Risk
1
2007
747
0.060
Why?
Imidazoles
1
2006
199
0.060
Why?
Proto-Oncogene Proteins c-bcl-2
1
2005
171
0.060
Why?
Cyclin D3
1
2004
10
0.060
Why?
Cyclin D2
1
2004
14
0.060
Why?
Cyclin D
1
2024
6
0.060
Why?
Proteasome Inhibitors
1
2004
60
0.060
Why?
NEDD8 Protein
1
2024
11
0.060
Why?
Thiophenes
1
2005
60
0.060
Why?
Heat-Shock Proteins
1
2005
194
0.060
Why?
Prospective Studies
2
2021
6033
0.060
Why?
Retinoblastoma Protein
1
2004
77
0.060
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2024
39
0.060
Why?
BRCA2 Protein
1
2024
43
0.060
Why?
Cyclin-Dependent Kinases
1
2004
85
0.060
Why?
BRCA1 Protein
1
2024
67
0.060
Why?
Ataxia Telangiectasia Mutated Proteins
1
2024
93
0.060
Why?
Quinazolines
1
2005
175
0.060
Why?
Aminopyridines
1
2024
53
0.060
Why?
SMARCB1 Protein
1
2023
35
0.060
Why?
Neoplasm Proteins
1
2008
667
0.050
Why?
Enhancer of Zeste Homolog 2 Protein
1
2023
57
0.050
Why?
Anemia
1
2007
340
0.050
Why?
Phenylacetates
1
2003
23
0.050
Why?
Nuclear Proteins
2
2023
1266
0.050
Why?
Drug Administration Routes
1
2003
30
0.050
Why?
Ipilimumab
1
2022
45
0.050
Why?
Phosphatidylinositol 3-Kinases
1
2024
340
0.050
Why?
MAP Kinase Signaling System
1
2024
315
0.050
Why?
Physicians
1
2009
584
0.050
Why?
Glutamine
1
2003
195
0.050
Why?
DNA Helicases
1
2023
224
0.050
Why?
Germ-Line Mutation
1
2024
313
0.050
Why?
Mixed Function Oxygenases
1
2002
32
0.050
Why?
Mitogen-Activated Protein Kinase Kinases
1
2022
83
0.050
Why?
Cell Cycle
1
2004
614
0.050
Why?
Europe
1
2023
374
0.050
Why?
Phenytoin
1
2002
64
0.050
Why?
Lymphoma
1
2005
321
0.050
Why?
DNA-Binding Proteins
2
2024
2047
0.050
Why?
Vascular Endothelial Growth Factor A
1
2024
413
0.050
Why?
Proto-Oncogene Proteins p21(ras)
1
2022
156
0.050
Why?
Proto-Oncogene Proteins
1
2004
550
0.050
Why?
Cytochrome P-450 Enzyme System
1
2002
136
0.050
Why?
Clinical Protocols
1
2022
235
0.050
Why?
CD56 Antigen
1
2020
26
0.050
Why?
Biomarkers, Tumor
2
2019
1430
0.050
Why?
Decision Making
1
2006
651
0.040
Why?
Response Evaluation Criteria in Solid Tumors
1
2020
8
0.040
Why?
Surveys and Questionnaires
1
2010
3666
0.040
Why?
DNA Repair Enzymes
2
2011
40
0.040
Why?
DNA Modification Methylases
2
2011
43
0.040
Why?
Pyrimidinones
1
2019
40
0.040
Why?
Drugs, Generic
1
2019
13
0.040
Why?
Community Participation
1
2019
44
0.040
Why?
Sodium
1
2020
291
0.040
Why?
Risk Assessment
2
2005
3316
0.040
Why?
Retreatment
1
2019
88
0.040
Why?
Anticonvulsants
1
2002
371
0.040
Why?
Patient Rights
1
2019
50
0.040
Why?
Focus Groups
1
2019
199
0.040
Why?
Combined Modality Therapy
3
2008
1239
0.040
Why?
Family
2
2016
579
0.040
Why?
Multimodal Imaging
1
2019
111
0.040
Why?
Algorithms
1
2005
1592
0.040
Why?
Microtubules
1
2018
197
0.040
Why?
Time Factors
2
2004
6217
0.040
Why?
Pyrazoles
1
2019
303
0.040
Why?
Immunophenotyping
1
2018
330
0.040
Why?
Neoplasm Grading
1
2018
267
0.030
Why?
Tumor Suppressor Proteins
2
2011
467
0.030
Why?
Dexamethasone
2
2012
272
0.030
Why?
Flow Cytometry
1
2018
803
0.030
Why?
United States Food and Drug Administration
1
2016
148
0.030
Why?
Patient Safety
1
2019
394
0.030
Why?
Interdisciplinary Communication
1
2016
134
0.030
Why?
Proportional Hazards Models
2
2011
1305
0.030
Why?
Pilot Projects
1
2018
1388
0.030
Why?
Rhodamines
1
2014
22
0.030
Why?
Immunohistochemistry
1
2018
1687
0.030
Why?
Infant, Newborn
3
2017
8108
0.030
Why?
Hydrolysis
1
2014
155
0.030
Why?
Transcription Factors
1
2023
2585
0.030
Why?
High-Throughput Screening Assays
1
2014
96
0.030
Why?
Neoplasm Transplantation
1
2014
369
0.030
Why?
Infusions, Intraventricular
1
2012
12
0.030
Why?
Mice
3
2019
17494
0.030
Why?
Microscopy, Fluorescence
1
2014
330
0.030
Why?
Antibodies
1
2014
369
0.030
Why?
Retrospective Studies
3
2020
16021
0.020
Why?
Phosphoproteins
1
2014
399
0.020
Why?
Ki-67 Antigen
1
2011
113
0.020
Why?
Age Factors
2
2008
2802
0.020
Why?
Peptides
1
2014
794
0.020
Why?
Health Insurance Portability and Accountability Act
1
2008
19
0.020
Why?
State Government
1
2008
29
0.020
Why?
Biomarkers
1
2018
2946
0.020
Why?
Kaplan-Meier Estimate
1
2011
1005
0.020
Why?
Government Regulation
1
2008
42
0.020
Why?
Darbepoetin alfa
1
2007
15
0.020
Why?
Drug Therapy, Combination
1
2011
1151
0.020
Why?
Pharmacokinetics
1
2007
16
0.020
Why?
Microsatellite Instability
1
2007
36
0.020
Why?
Radiotherapy Dosage
1
2008
185
0.020
Why?
Bone Marrow Diseases
1
2008
40
0.020
Why?
DNA, Neoplasm
1
2008
300
0.020
Why?
Hematinics
1
2007
57
0.020
Why?
HCT116 Cells
1
2006
53
0.020
Why?
Cell Proliferation
1
2014
2306
0.020
Why?
Stem Cell Transplantation
1
2008
239
0.020
Why?
Hemoglobins
1
2007
301
0.020
Why?
Drug-Related Side Effects and Adverse Reactions
1
2008
255
0.020
Why?
Pulse Therapy, Drug
1
2004
7
0.020
Why?
Middle Aged
3
2014
25994
0.020
Why?
Biological Availability
1
2004
128
0.010
Why?
Meningitis
1
2005
99
0.010
Why?
Imatinib Mesylate
1
2004
44
0.010
Why?
Probability
1
2004
321
0.010
Why?
Biotransformation
1
2003
49
0.010
Why?
Spectrophotometry, Ultraviolet
1
2003
44
0.010
Why?
Ultraviolet Rays
1
2004
204
0.010
Why?
Catheters, Indwelling
1
2004
155
0.010
Why?
Practice Patterns, Physicians'
1
2008
712
0.010
Why?
Injections, Intraventricular
1
2002
65
0.010
Why?
Ondansetron
1
2002
10
0.010
Why?
Pineal Gland
1
2002
17
0.010
Why?
Pinealoma
1
2002
19
0.010
Why?
Feasibility Studies
1
2005
751
0.010
Why?
Melphalan
1
2002
49
0.010
Why?
Tumor Suppressor Protein p53
1
2006
715
0.010
Why?
Phenobarbital
1
2002
36
0.010
Why?
Enzyme Induction
1
2002
103
0.010
Why?
Etoposide
1
2002
117
0.010
Why?
Breast Neoplasms
1
2014
2477
0.010
Why?
Cytochrome P-450 CYP3A
1
2002
59
0.010
Why?
Cranial Irradiation
1
2002
69
0.010
Why?
Pregnancy
1
2014
7148
0.010
Why?
Multivariate Analysis
1
2004
1414
0.010
Why?
Protein Binding
1
2004
1741
0.010
Why?
Cohort Studies
1
2008
4706
0.010
Why?
Models, Biological
1
2003
1441
0.010
Why?
Seizures
1
2002
874
0.010
Why?
Disease Progression
1
2002
2025
0.010
Why?
Hematopoietic Stem Cell Transplantation
1
2002
1198
0.010
Why?
BERG's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (344)
Explore
_
Co-Authors (43)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_